IND approval for PII Stem Cell Trial for Stroke, Aldargen
- The clinical trial will test the use of ALD-401’s collection of stem cells as a treatment for stroke victims;
- The 100 or so participants in the clinical trial will receive an injection of ALD-401 stem cells 13 to 19 days after suffering a stroke;
- The trial will test the ability of the stem cell therapy to alleviate stroke damage;
- ALD-401 can be delivered about 2 weeks after a stroke and therefore has the potential to treat a large group of patients who have no therapeutic options.
Stroke represents the leading cause of disability in the US and the third leading cause of morbidity.
- The only product currently available for stroke treatment is an anti-clotting agent that must be administered within 3 hours of onset of the stroke;
- Because of this timing requirement, less than 5% of stroke patients receive the treatment.
Aldargen, a Durham, NC drug developer has had an $81M initial public offering pending since fall 2009.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.